Outset Medical, Inc. (OM) is a publicly traded company in the Healthcare — Medical - Devices industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Outset Medical, Inc. is a medical technology firm that specializes in developing hemodialysis systems. The company's primary product is the Tablo Hemodialysis System, a compact console designed to deliver dialysis treatment in various environments, including hospitals and patients' homes. This innovative system boasts integrated water purification, on-demand production of dialysate, and advanced software complete with connectivity features.
Analysis Summary
Outset Medical, Inc. reported revenue of $119.5M in the most recent fiscal year, growing at a 5-year CAGR of 19.1%.
Trailing-twelve-month margins: gross margin 41.8%, operating margin -56.1%, net margin -63.1%.
At the current price of $3.12, OM has negative trailing earnings (P/E not meaningful) and an ROE of -62.25%. Market capitalisation stands at $58M.
Balance sheet quality for OM: current ratio of 6.7, net cash position of $67.7M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price
| Price | $3.12 |
| Market Cap | $58M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.59 |
| EV / EBITDA | -2.42 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -62.25% |
| Return on Invested Capital | -32.84% |
| Return on Assets | -30.65% |
| Gross Margin | 41.76% |
| Operating Margin | -56.06% |
| Net Margin | -63.06% |
Financial Health
| Debt / Equity | 1.08 |
| Current Ratio | 5.19 |
What to look at in Healthcare / Pharma
The R&D pipeline is the invisible asset. Patents expiring = revenues evaporating. Look at innovation and cash flow.
- R&D / Revenue — Shows investment in future pipeline. Serious pharma reinvests 15-20%
- 5y EPS growth — After patent expirations, are they still growing?
- Gross margin — Branded pharma >70%. Generics much lower — defines the business type
- FCF / Net Income — Earnings quality — big pharma should convert >90%
- ROIC — Capital reinvested efficiently — key in pharma due to long R&D cycles
- Net debt / EBITDA — Pharma acquisitions pile up debt — watch the post-M&A picture
- P/E vs own 10y history — The best comparison is with its own history, not with peers
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| OM | Outset Medical, Inc. | $58M | 0.59 | -62.3% | |
| ABT | Abbott Laboratories | $177.1B | 32.49 | 3.45 | 10.5% |
| 0Y6X.L | Medtronic Plc | $125.7B | |||
| MDT | Medtronic plc | $118.5B | 22.97 | 2.39 | 10.6% |
| SYK | Stryker Corporation | $109.2B | 29.95 | 4.66 | 16.4% |
| 0R2S.L | Stryker Corporation | $107.9B | 28.37 | 4.41 | 16.4% |
| 0HOY.L | Boston Scientific Corporation | $65.3B | 17.84 | 2.62 | 14.9% |
| BSX | Boston Scientific Corporation | $65.3B | 17.73 | 2.61 | 14.9% |
Price Performance
| 1 month | -25.36% |
| 3 months | -38.22% |
| Year-to-date | -15.90% |
| 1 year | -77.60% |
| 3 years | -98.30% |
| 5 years | -99.62% |
52-Week Range
| 52-week High | $16.16 |
| 52-week Low | $3.00 |
| Avg Volume (90d) | 194K |
Related companies: CATX · HSDT · INGN · NNOX · OMI · QTRX · SI
Explore sector: Healthcare · Medical - Devices
More sections of OM: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks